Enovix Corporation
$778.81M- Market cap
- $761.49M
- Debt
- +$529.37M
- Cash
- −$512.04M
Capital structure 59% equity / 41% debt · EV / Revenue 24.47x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ENVX stock price vs ACAD: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ACAD's multiple
Needs ACAD P/S.
Implied fair value · at ENVX's multiple
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ENVX FY 2025 (ended Dec 28, 2025) · ACAD FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Ten period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
Market cap plus debt, less cash.
Capital structure 59% equity / 41% debt · EV / Revenue 24.47x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Enovix Corporation · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
ACADIA PHARMACEUTICALS INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
1.95x
0.25x
Net debt / EBITDA
Leverage against operating earnings
-0.15x
0.85x
Cash and equivalents
Liquid reserves on the balance sheet
$512.04M
$177.70M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
QuantumScape Corp
ENVX vs QS
Eos Energy Enterprises, Inc.
ENVX vs EOSE
Microvast Holdings, Inc.
ENVX vs MVST
AEHR TEST SYSTEMS
ENVX vs AEHR
SUPERNUS PHARMACEUTICALS, INC.
ENVX vs SUPN
Sage Therapeutics, Inc.
ENVX vs SAGE
Jazz Pharmaceuticals plc
ENVX vs JAZZ
Alkermes plc.
ENVX vs ALKS
Harmony Biosciences Holdings, Inc.
ENVX vs HRMY
Krystal Biotech, Inc.
ENVX vs KRYS
$529.37M
$306.51M
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.